部分遗传性皮肤病的治疗进展

doi:10.35541/cjd.20220001

Abstract

Abstract: 【Abstract】 Genodermatoses are a relatively independent type of skin diseases, with early onset, complex clinical manifestations and multiple system involvement. Current treatments of genodermatoses are still limited with poor therapeutic effect, and the quality of life of patients is greatly affected. This review summarizes prospective treatment methods of some hereditary skin diseases and related research progress, including innovative application of traditional medicines, biologics and small-molecule targeted drugs, stem cell therapy and gene editing, aiming to provide more reference for clinicians.

Key words: Skin diseases, genetic, Therapy, Biological agents, Stem cells, Small molecular targeted drugs, Gene editing

Jin Liang, Liu Ling. Treatment of some genodermatoses[J]. Chinese Journal of Dermatology, 2022, 55(8): 735-739.doi:10.35541/cjd.20220001

References ［49］

［1］	Lincoln V, Cogan J, Hou Y, et al. Gentamicin induces LAMB3 nonsense mutation readthrough and restores functional laminin 332 in junctional epidermolysis bullosa［J］. Proc Natl Acad Sci U S A, 2018,115（28）:E6536⁃E6545. doi: 10.1073/pnas.18031 54115.
［2］	Hammersen J, Neuner A, Wild F, et al. Attenuation of severe generalized junctional epidermolysis bullosa by systemic treatment with gentamicin［J］. Dermatology, 2019,235（4）:315⁃322. doi: 10.1159/000499906.
［3］	Kwong A, Cogan J, Hou Y, et al. Gentamicin induces laminin 332 and improves wound healing in junctional epidermolysis bullosa patients with nonsense mutations［J］. Mol Ther, 2020,28（5）:1327⁃1338. doi: 10.1016/j.ymthe.2020.03.006.
［4］	Woodley DT, Cogan J, Hou Y, et al. Gentamicin induces functional type VII collagen in recessive dystrophic epidermolysis bullosa patients［J］. J Clin Invest, 2017,127（8）:3028⁃3038. doi: 10.1172/JCI92707.
［5］	Vishwanath T, Agrawal S, Ghate S, et al. Intrabullous injection: a novel, painless technique of drug delivery in localized bullous dermatoses［J］. J Am Acad Dermatol, 2019,81（6）:e161⁃e163. doi: 10.1016/j.jaad.2019.06.039.
［6］	李越, 梁键莹, 程茹虹, 等. 庆大霉素软膏治疗无义突变引起的营养不良性大疱性表皮松解症的临床疗效观察［J］. 中国皮肤性病学杂志, 2020,34（6）:650⁃654. doi: 10.13735/j.cjdv. 1001⁃7089.201909131.
［7］	Wang J, Liu Y, Liu F, et al. Loss⁃of⁃function mutation in PMVK causes autosomal dominant disseminated superficial poro⁃keratosis［J］. Sci Rep, 2016,6:24226. doi: 10.1038/srep24226.
［8］	Zhang SQ, Jiang T, Li M, et al. Exome sequencing identifies MVK mutations in disseminated superficial actinic porokeratosis［J］. Nat Genet, 2012,44（10）:1156⁃1160. doi: 10.1038/ng.2409.
［9］	Atzmony L, Khan HM, Lim YH, et al. Second⁃hit, postzygotic PMVK and MVD mutations in linear porokeratosis［J］. JAMA Dermatol, 2019,155（5）:548⁃555. doi: 10.1001/jamadermatol. 2019.0016.
［10］	Kubo A, Sasaki T, Suzuki H, et al. Clonal expansion of second⁃hit cells with somatic recombinations or C>T transitions form porokeratosis in MVD or MVK mutant heterozygotes［J］. J Invest Dermatol, 2019,139（12）:2458⁃2466.e9. doi: 10.1016/j.jid.2019. 05.020.
［11］	Paller AS, van Steensel MA, Rodriguez⁃Martín M, et al. Pathogenesis⁃based therapy reverses cutaneous abnormalities in an inherited disorder of distal cholesterol metabolism［J］. J Invest Dermatol, 2011,131（11）:2242⁃2248. doi: 10.1038/jid. 2011.189.
［12］	Atzmony L, Lim YH, Hamilton C, et al. Topical cholesterol/lovastatin for the treatment of porokeratosis: a pathogenesis⁃directed therapy［J］. J Am Acad Dermatol, 2020,82（1）:123⁃131. doi: 10.1016/j.jaad.2019.08.043.
［13］	Tomsitz D, Biedermann T. Successful treatment of disseminated superficial actinic porokeratosis with topical 2% cholesterol/ 2% lovastatin cream: a case series with 7 patients［J］. J Eur Acad Dermatol Venereol, 2022,36（1）:e52⁃e54. doi: 10.1111/jdv.17619.
［14］	Byth LA, Byth J. Topical simvastatin⁃cholesterol for disseminated superficial actinic porokeratosis: an open⁃label, split⁃body clinical trial［J］. Australas J Dermatol, 2021,62（3）:310⁃313. doi: 10.1111/ajd.13601.
［15］	Shimada BK, Pomozi V, Zoll J, et al. ABCC6, pyrophosphate and ectopic calcification: therapeutic solutions［J］. Int J Mol Sci, 2021,22（9）doi: 10.3390/ijms22094555.
［16］	Yoo JY, Blum RR, Singer GK, et al. A randomized controlled trial of oral phosphate binders in the treatment of pseudoxanthoma elasticum［J］. J Am Acad Dermatol, 2011,65（2）:341⁃348. doi: 10.1016/j.jaad.2010.05.023.
［17］	LaRusso J, Jiang Q, Li Q, et al. Ectopic mineralization of connective tissue in Abcc6-/- mice: effects of dietary modifications and a phosphate binder⁃⁃a preliminary study［J］. Exp Dermatol, 2008,17（3）:203⁃207. doi: 10.1111/j.1600⁃0625. 2007.00645.x.
［18］	Dabisch⁃Ruthe M, Kuzaj P, Götting C, et al. Pyrophosphates as a major inhibitor of matrix calcification in Pseudoxanthoma elasticum［J］. J Dermatol Sci, 2014,75（2）:109⁃120. doi: 10. 1016/j.jdermsci.2014.04.015.
［19］	Li Q, Kingman J, Sundberg JP, et al. Etidronate prevents, but does not reverse, ectopic mineralization in a mouse model of pseudoxanthoma elasticum （Abcc6（-/-））［J］. Oncotarget, 2018,9（56）:30721⁃30730. doi: 10.18632/oncotarget.10738.
［20］	Kranenburg G, de Jong PA, Bartstra JW, et al. Etidronate for prevention of ectopic mineralization in patients with pseudoxanthoma elasticum［J］. J Am Coll Cardiol, 2018,71（10）:1117⁃1126. doi: 10.1016/j.jacc.2017.12.062.
［21］	Schantl AE, Verhulst A, Neven E, et al. Inhibition of vascular calcification by inositol phosphates derivatized with ethylene glycol oligomers［J］. Nat Commun, 2020,11（1）:721. doi: 10. 1038/s41467⁃019⁃14091⁃4.
［22］	Omarjee L, Nitschke Y, Verschuere S, et al. Severe early⁃onset manifestations of pseudoxanthoma elasticum resulting from the cumulative effects of several deleterious mutations in ENPP1, ABCC6 and HBB: transient improvement in ectopic calcification with sodium thiosulfate［J］. Br J Dermatol, 2020,183（2）:367⁃372. doi: 10.1111/bjd.18632.
［23］	Fogel AL, Hill S, Teng JM. Advances in the therapeutic use of mammalian target of rapamycin （mTOR） inhibitors in dermatology［J］. J Am Acad Dermatol, 2015,72（5）:879⁃889. doi: 10.1016/j.jaad.2015.01.014.
［24］	Koenig MK, Bell CS, Hebert AA, et al. Efficacy and safety of topical rapamycin in patients with facial angiofibromas secondary to tuberous sclerosis complex: the TREATMENT randomized clinical trial［J］. JAMA Dermatol, 2018,154（7）:773⁃780. doi: 10.1001/jamadermatol.2018.0464.
［25］	Liu YX, Zhang J, Nie XL, et al. The effect of topical sirolimus on superficial Kaposiform haemangioendothelioma［J］. Australas J Dermatol, 2021,62（2）:e329⁃e331. doi: 10.1111/ajd.13499.
［26］	Lee GH, Lekwuttikarn R, Tafoya E, et al. Transcriptomic repositioning analysis identifies mTOR inhibitor as potential therapy for epidermolysis bullosa simplex［J］. J Invest Dermatol, 2022,142（2）:382⁃389. doi: 10.1016/j.jid.2021.07.170.
［27］	Deininger M, Buchdunger E, Druker BJ. The development of imatinib as a therapeutic agent for chronic myeloid leukemia［J］. Blood, 2005,105（7）:2640⁃2653. doi: 10.1182/blood⁃2004⁃08⁃3097.
［28］	Moffat JG, Rudolph J, Bailey D. Phenotypic screening in cancer drug discovery ⁃ past, present and future［J］. Nat Rev Drug Discov, 2014,13（8）:588⁃602. doi: 10.1038/nrd4366.
［29］	Bedard PL, Hyman DM, Davids MS, et al. Small molecules, big impact: 20 years of targeted therapy in oncology［J］. Lancet, 2020,395（10229）:1078⁃1088. doi: 10.1016/S0140⁃6736（20）30164⁃1.
［30］	Strumberg D, Clark JW, Awada A, et al. Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors［J］. Oncologist, 2007,12（4）:426⁃437. doi: 10.1634/theoncologist.12⁃4⁃426.
［31］	Flaherty KT, Puzanov I, Kim KB, et al. Inhibition of mutated, activated BRAF in metastatic melanoma［J］. N Engl J Med, 2010,363（9）:809⁃819. doi: 10.1056/NEJMoa1002011.
［32］	Sekulic A, Migden MR, Oro AE, et al. Efficacy and safety of vismodegib in advanced basal⁃cell carcinoma［J］. N Engl J Med, 2012,366（23）:2171⁃2179. doi: 10.1056/NEJMoa1113713.
［33］	Verstovsek S, Gotlib J, Mesa RA, et al. Long⁃term survival in patients treated with ruxolitinib for myelofibrosis: COMFORT⁃I and ⁃II pooled analyses［J］. J Hematol Oncol, 2017,10（1）:156. doi: 10.1186/s13045⁃017⁃0527⁃7.
［34］	Attwood MM, Fabbro D, Sokolov AV, et al. Trends in kinase drug discovery: targets, indications and inhibitor design［J］. Nat Rev Drug Discov, 2021,20（11）:839⁃861. doi: 10.1038/s41573⁃021⁃00252⁃y.
［35］	Liddle J, Beneton V, Benson M, et al. A potent and selective kallikrein⁃5 inhibitor delivers high pharmacological activity in skin from patients with Netherton syndrome［J］. J Invest Dermatol, 2021,141（9）:2272⁃2279. doi: 10.1016/j.jid.2021.01. 029.
［36］	Murase C, Takeichi T, Taki T, et al. Successful dupilumab treatment for ichthyotic and atopic features of Netherton syndrome［J］. J Dermatol Sci, 2021,102（2）:126⁃129. doi: 10. 1016/j.jdermsci.2021.03.003.
［37］	Wang J, Yu L, Zhang S, et al. Successful treatment of Netherton syndrome with dupilumab: a case report and review of the literature［J］. J Dermatol, 2022,49（1）:165⁃167. doi: 10.1111/1346⁃8138.16253.
［38］	Steuer AB, Cohen DE. Treatment of Netherton syndrome with dupilumab［J］. JAMA Dermatol, 2020,156（3）:350⁃351. doi: 10.1001/jamadermatol.2019.4608.
［39］	Chello C, Sernicola A, Paolino G, et al. Effects of dupilumab in type 1 neurofibromatosis coexisting with severe atopic dermatitis［J］. An Bras Dermatol, 2021,96（5）:638⁃640. doi: 10.1016/j.abd.2020.10.006.
［40］	De Luca M, Aiuti A, Cossu G, et al. Advances in stem cell research and therapeutic development［J］. Nat Cell Biol, 2019,21（7）:801⁃811. doi: 10.1038/s41556⁃019⁃0344⁃z.
［41］	Hirsch T, Rothoeft T, Teig N, et al. Regeneration of the entire human epidermis using transgenic stem cells［J］. Nature, 2017,551（7680）:327⁃332. doi: 10.1038/nature24487.
［42］	Abeona Therapeutics. VIITAL: phase III clinical trial of EB⁃101 for RDEB［EB/OL］.［2022⁃4⁃7］. https://www.debra.org/viital⁃phase⁃iii⁃clinical⁃trial⁃eb⁃101⁃rdeb.
［43］	Shi N, Yang Q, Zhang H, et al. Restoration of dystrophin expression in mice by suppressing a nonsense mutation through the incorporation of unnatural amino acids［J］. Nat Biomed Eng, 2022,6（2）:195⁃206. doi: 10.1038/s41551⁃021⁃00774⁃1.
［44］	Shinkuma S, Guo Z, Christiano AM. Site⁃specific genome editing for correction of induced pluripotent stem cells derived from dominant dystrophic epidermolysis bullosa［J］. Proc Natl Acad Sci U S A, 2016,113（20）:5676⁃5681. doi: 10.1073/pnas.15120 28113.
［45］	Kocher T, Peking P, Klausegger A, et al. Cut and paste: efficient homology⁃directed repair of a dominant negative KRT14 mutation via CRISPR/Cas9 nickases［J］. Mol Ther, 2017,25（11）:2585⁃2598. doi: 10.1016/j.ymthe.2017.08.015.
［46］	Jacków J, Guo Z, Hansen C, et al. CRISPR/Cas9⁃based targeted genome editing for correction of recessive dystrophic epidermolysis bullosa using iPS cells［J］. Proc Natl Acad Sci U S A, 2019,116（52）:26846⁃26852. doi: 10.1073/pnas.190708 1116.
［47］	Benati D, Miselli F, Cocchiarella F, et al. CRISPR/Cas9⁃mediated in situ correction of LAMB3 gene in keratinocytes derived from a junctional epidermolysis bullosa patient［J］. Mol Ther, 2018,26（11）:2592⁃2603. doi: 10.1016/j.ymthe.2018.07. 024.
［48］	Wu W, Lu Z, Li F, et al. Efficient in vivo gene editing using ribonucleoproteins in skin stem cells of recessive dystrophic epidermolysis bullosa mouse model［J］. Proc Natl Acad Sci U S A, 2017,114（7）:1660⁃1665. doi: 10.1073/pnas.1614775114.
［49］	Luan XR, Chen XL, Tang YX, et al. CRISPR/Cas9⁃mediated treatment ameliorates the phenotype of the epidermolytic palmoplantar keratoderma⁃like mouse［J］. Mol Ther Nucleic Acids, 2018,12:220⁃228. doi: 10.1016/j.omtn.2018.05.005.

[1]	Bao Yingqiu, Zhang Yanjun, Li Bo, Gong Jing, Fu Yu, Xu Zhe. Gene therapy for recessive dystrophic epidermolysis bullosa [J]. Chinese Journal of Dermatology, 2022, 55(8): 739-743.
[2]	Fan Birao, Chen Xixue, Wang Mingyue. Retrospective analysis of efficacy and safety of minocycline alone or in combination with low-dose glucocorticoids in the treatment of 15 cases of pemphigus erythematosus and 9 cases of pemphigus herpetiformis [J]. Chinese Journal of Dermatology, 2022, 55(8): 676-681.
[3]	Cao Miao, Chong Shan, Hu Xinyuan, Zhu Xuejun, Wang Mingyue. Analysis of skin and mucosal infections and their management after primary tumor resection in patients with paraneoplastic pemphigus [J]. Chinese Journal of Dermatology, 2022, 55(8): 669-675.
[4]	Xu Zhe. Some thoughts on hereditary dermatoses [J]. Chinese Journal of Dermatology, 2022, 55(8): 651-652.
[5]	Wang Yuan, Li Zhiliang, Li Suo, Jing Ke, Sun Chao, Liang Guirong, Zhang Hanmei, Feng Suying. Clinical and immunoserological features of 7 cases of anti-p200 pemphigoid [J]. Chinese Journal of Dermatology, 2022, 55(7): 557-561.
[6]	Gao Zirui, Zhao Pei, Dou Yuanqing, Liu Ping, Zhang Jianzhong. Efficacy and safety of dupilumab in the treatment of adult prurigo nodularis [J]. Chinese Journal of Dermatology, 2022, 55(7): 562-565.
[7]	Wang Lingyan, Pan Jing, Miao Gang, Chang Xiaodan, Jin Qiuzi, Guo Ningning, Zhang Jiayu. Analysis of difficult-to-treat sites in patients with psoriasis who received biological therapy [J]. Chinese Journal of Dermatology, 2022, 55(7): 583-587.
[8]	Zhang Ning, Li Shu, Li Jing . Efficacy of immune checkpoint inhibitors and targeted therapy in adjuvant treatment of resectable melanoma: a network meta-analysis [J]. Chinese Journal of Dermatology, 2022, 55(7): 603-609.
[9]	Wen Guangdong, Mao Dandan, Zhang Yuanyuan, Dou Yuanqing, Zhao Pei, Wu Chenyu, Zhang Jianzhong. A case of generalized lichen amyloidosis treated with dupilumab: the first case reported in China [J]. Chinese Journal of Dermatology, 2022, 55(6): 508-510.
[10]	Working Group for Atopic Dermatitis, Chinese Society of Dermatology, Working Group for Children′s Diseases, Chinese Society of Dermatology. Treatment of atopic dermatitis with dupilumab: an expert consensus [J]. Chinese Journal of Dermatology, 2022, 55(6): 465-470.
[11]	Zhao Liuqi, Chen Yan, Chen Danyang, Fan Birao, Wang Rui, Shang Panpan, Chen Xixue, Zhu Xuejun, Wang Mingyue. Efficacy and safety of dupilumab in the treatment of 21 cases of bullous pemphigoid: a retrospective study [J]. Chinese Journal of Dermatology, 2022, 55(6): 480-485.
[12]	Huang Xin, Chen Xiaoyun, Li Yaping, Liang Xingkun, Zhang Guiying, Zhou Ying, Zhan Yi, Luo Shuaihantian, Liao Jieyue, Xiao Rong, Long Hai. Efficacy and safety of dupilumab in the treatment of 123 cases of atopic dermatitis [J]. Chinese Journal of Dermatology, 2022, 55(6): 486-493.
[13]	Zhang Xiao, Chen Fengming, Liu Lin, Luo Li, Guo Jin, Gao Tianwen, Shi Qiong. Analysis of clinicopathological features and prognosis of 163 cases of stage Ⅰ cutaneous melanoma [J]. Chinese Journal of Dermatology, 2022, 55(5): 389-394.
[14]	Zhang Shuchang, Ge Yicheng, Zhao Zhihao, Guo Pan, Xing Weibin, Hu Lizhi. Regulatory role of the transcriptional coactivator Mediator 1 in skin hair regeneration and its mechanisms [J]. Chinese Journal of Dermatology, 2022, 55(5): 401-407.
[15]	Xia Na, Gao Chao, Liu Xuan, Zou Dongxu, Ji Guangju, Cai Hong, . Role of umbilical cord mesenchymal stem cell-derived exosomes in acute skin wound healing [J]. Chinese Journal of Dermatology, 2022, 55(5): 382-388.

Treatment of some genodermatoses

PDF

Knowledge

Abstract

Cite this article

share this article

References ［49］

Related Articles 15

Metrics

Comments

Recommended 10